Group 1: Company Operations and Changes - In 2025, the company optimized its offline sales channels and improved its management team, which aligned with expectations [2] - The offline market is crucial for the company's long-term development, necessitating adjustments for better profitability [2] - The company aims to maintain stable pricing across all channels, managing price through promotions during peak sales periods [3] Group 2: Sales Channel Adjustments - The optimization led to a reduction in the number of distributors, focusing on higher quality partnerships with service-oriented distributors [3] - The company expects positive performance in offline sales for 2026 due to improved channel quality and team enhancements [3] Group 3: Product Development and Future Plans - The medical aesthetics channel remains a key focus, with plans to increase R&D efforts and accelerate product launches [3] - Progress is being made on injectable products, including a humanized collagen product that has completed clinical trials and is preparing for submission [3]

Investment Rating - The investment rating for the social services industry is "Positive" (maintained) [1] Core Insights - The report highlights a robust recovery in the Hong Kong economy, with GDP growth of 3.5% in 2025 and a notable increase in retail sales, which rose by 5.5% year-on-year in January 2026 [25][27] - The residential property market in Hong Kong is showing signs of recovery, with the leading index rising by 8% year-on-year as of February 22, 2026, indicating a positive trend in housing prices [28][30] - The medical aesthetics sector, particularly the company "四环医药," is experiencing significant growth, with revenues exceeding 1.4 billion yuan and profits over 700 million yuan in 2025, reflecting a year-on-year growth rate of over 90% [43][44] Summary by Sections Government Work Report - The 2026 government work report emphasizes boosting consumption as a core strategy for expanding domestic demand, introducing measures to increase income for low-income groups and enhance consumer spending capacity [13][14] - New policies include a 100 billion yuan special fund to promote domestic demand and support for service consumption [13][16] Economic Recovery in Hong Kong - Hong Kong's economy is on a steady recovery path, with GDP growth of 3.5% in 2025 and a 3.8% increase in Q4, driven by both consumption and exports [26][27] - Retail sales are projected to reach approximately 410 billion HKD in 2026, marking an 8% year-on-year increase, with significant growth expected in jewelry, clothing, and cosmetics [27] Real Estate Market Trends - The residential property market is recovering, with the leading index reaching 149.41 points, an 8% increase year-on-year, and the private residential price index showing a 4.9% increase, marking eight consecutive months of growth [28][32] - The "cooling" measures in the property market have been fully implemented, reducing transaction costs and stimulating market liquidity [38][39] Medical Aesthetics Sector - The medical aesthetics division of "四环医药" is becoming a major revenue and profit driver, with a projected revenue of over 2.5 billion yuan in 2025, reflecting a growth rate exceeding 30% [43][44] - The company has a diverse product matrix, including successful products like "乐提葆" and "铂安润," which are contributing significantly to its revenue growth [48][49]

Investment Rating - The investment rating for the social services industry is "Positive" (maintained) [1] Core Insights - The report highlights a robust recovery in the Hong Kong economy, with GDP growth of 3.5% in 2025 and a notable increase in retail sales, which rose by 5.5% year-on-year in January 2026 [25][27] - The residential property market in Hong Kong is showing signs of recovery, with the leading index rising by 8% year-on-year as of February 22, 2026, indicating a positive trend in housing prices [28][30] - The medical aesthetics sector, particularly the company "Four Ring Pharmaceutical," is experiencing significant growth, with revenues exceeding 1.4 billion yuan and profits surpassing 700 million yuan in 2025, reflecting a year-on-year growth rate of over 90% [43][44] Summary by Sections Government Work Report - The 2026 government work report emphasizes boosting consumption as a core strategy for expanding domestic demand, introducing measures to increase income for low-income groups and enhance consumer spending capacity [13][14] - New policies include a 1 billion yuan special fund to promote domestic demand and support for service consumption [13][16] Economic Recovery in Hong Kong - Hong Kong's economy is on a steady recovery path, with GDP growth of 3.5% in 2025 and a 3.8% increase in Q4, driven by both consumption and exports [26][27] - Retail sales are projected to reach approximately 410 billion HKD in 2026, marking an 8% increase year-on-year, with significant growth expected in jewelry, clothing, and cosmetics [27][28] Real Estate Market Trends - The residential property market is recovering, with the leading index reaching 149.41 points, an 8% increase year-on-year, and the private residential price index showing a 4.9% increase, marking eight consecutive months of growth [28][32] - The "cooling" measures in the property market have been fully implemented, reducing transaction costs and stimulating market liquidity [38][39] Medical Aesthetics Sector - Four Ring Pharmaceutical's medical aesthetics division is becoming a major revenue and profit driver, with a projected revenue of at least 2.5 billion yuan in 2025, reflecting a growth rate exceeding 30% [43][44] - The company has a diverse product matrix, including successful products like "Le Ti Bao" botulinum toxin and "Platinum Hyaluronic Acid," which are contributing significantly to its performance [44][48]

Investment Rating - The investment rating for the retail industry is "Positive" (maintained) [1] Core Insights - The report highlights the strong performance of domestic brands during the 38 promotional event, with significant sales figures and consumer demand for effective skincare products [23][25] - The report emphasizes the importance of emotional consumption themes and recommends high-quality companies in high-growth sectors [6][30][31] Summary by Sections Retail and Social Services Market Review - The retail and social services indices reported declines of 3.91% and 3.63% respectively during the week of March 2 to March 6, 2026 [5][15] - Year-to-date, the retail index has decreased by 6.82%, while the social services index has increased by 3.01% [15][16] Industry Dynamics - Domestic brands performed well during the 38 promotional event, with leading brands like Proya achieving significant sales [23] - The report notes that the skincare product category is seeing strong demand, particularly for effective and functional products [23][25] Investment Recommendations - Investment focus areas include: - **Gold and Jewelry**: Recommend brands with differentiated product offerings such as Laopuhuang and Chaohongji [6][30] - **Offline Retail**: Highlight companies adapting to trends like Yonghui Supermarket and Aiyingshi [6][30] - **Cosmetics**: Focus on brands that meet emotional value and safety innovation, recommending brands like Maogeping and Proya [6][31] - **Medical Aesthetics**: Suggest companies with differentiated products and expanding chains, such as Meilitiantian Medical Health and Aimeike [6][31] Company Performance Highlights - **Shangmei Co.**: Expected revenue of 9.1-9.2 billion yuan for 2025, with a year-on-year growth of 34.0%-35.4% [27] - **Zhou Dafu**: Achieved a retail value increase of 17.8% year-on-year in Q3 2026 [32] - **Yonghui Supermarket**: Anticipated revenue decline but undergoing significant operational adjustments [32]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, highlighting potential growth despite recent market underperformance [2][3]. Core Insights - The cosmetics and medical beauty sector has underperformed the market, with the Shenwan Beauty Care Index declining by 3.0% from February 27 to March 6, 2026. The Shenwan Cosmetics Index fell by 4.9%, while the Shenwan Personal Care Products Index decreased by 0.7% [3][4]. - Upbeauty Co., Ltd. has exceeded expectations for 2025, forecasting revenue between 9.1 billion and 9.2 billion yuan, representing a year-on-year increase of 34.0%-35.4%. The net profit attributable to shareholders is expected to be between 1.14 billion and 1.16 billion yuan, reflecting a growth of 41.9%-44.4% [9]. - The report emphasizes the importance of Upbeauty’s core anti-aging product line, which is continuously iterating to meet the upgrading trend of domestic anti-aging consumption, thereby enhancing both brand and product strength [9]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown weaker performance compared to the overall market, with significant declines in key indices [3][4]. - The report notes that the Shenwan Cosmetics Index's decline of 4.9% is notably worse than the Shenwan A Index by 2.5 percentage points [4]. Company Highlights - Upbeauty Co., Ltd. is highlighted for its strong performance, with a positive earnings forecast for 2025, driven by its core business and product innovation [9]. - Huaxi Biological (688363.SH) reported a net profit of 291 million yuan for 2025, a year-on-year increase of 67.03%, indicating a successful strategic transformation [3][9]. - Yixian E-commerce reported a revenue of 4.3 billion yuan for 2025, a 26.7% increase year-on-year, marking its first annual Non-GAAP profit since its listing [22]. Market Trends - The report identifies a structural growth phase in the nutrition and health food market, with a market size reaching over 100 billion yuan, significantly outpacing traditional food sectors [11]. - The online DTC channel is recognized as a core growth engine for the industry, with companies like Xizi Health achieving over 98% of their revenue from online sales [11]. Investment Recommendations - The report recommends focusing on companies with strong channel and brand matrices, such as Upbeauty Co., Ltd. and Mao Ge Ping, which are expected to see high GMV growth [3][9]. - It also suggests monitoring companies with improving performance metrics, including Proya, Marubi, and Huaxi Biological, as well as those in the maternal and infant sector like Shengbeila and Kidswant [3].

Investment Rating - The investment rating for the retail industry is "Positive" (maintained) [1] Core Insights - The report highlights the strong performance of domestic brands during the 38 promotional event, with significant sales figures and consumer demand for effective skincare products [23][25] - The report emphasizes the importance of emotional consumption themes and recommends high-quality companies in high-growth sectors [6][30][31] Summary by Sections Retail and Social Services Market Review - The retail and social services indices reported declines of 3.91% and 3.63% respectively during the week of March 2 to March 6, 2026, ranking 25th and 23rd among 31 primary industries [5][15] - Year-to-date, the retail index has decreased by 6.82%, while the social services index has increased by 3.01% [12][15] Industry Dynamics - The 38 promotional event saw domestic brands excel, with significant sales figures reported from live streaming platforms [23][25] - Key brands such as Pechoin and Betainy led in product selection and sales performance during the promotional period [23][24] Investment Recommendations - Investment focus areas include: - Gold and jewelry brands with differentiated product offerings, recommending companies like Laopuhuangjin and Chaohongji [6][30] - Offline retail companies adapting to market changes, recommending Yonghui Supermarket and Aiyingshi [6][30] - Domestic beauty brands that emphasize emotional value and innovative ingredients, recommending Maogeping and Shangmei [6][31] - Medical aesthetics firms with differentiated products, recommending Meilitiantian and Aimeike [6][31] Company Performance Highlights - Shangmei Co. is projected to achieve revenues of 9.1-9.2 billion yuan, a year-on-year increase of 34.0%-35.4%, with net profits expected to reach 1.14-1.16 billion yuan, up 41.9%-44.4% [27][29] - Zhou Dafu reported a retail value increase of 17.8% year-on-year for FY2026Q3, driven by product structure optimization [32]

Core Viewpoint - In a slowing global beauty industry, Galderma, a skin-focused company, has achieved significant growth, with net sales surpassing $5 billion for the first time, reaching $5.207 billion (approximately 358.92 billion RMB), a year-on-year increase of 17.7% [3][4]. Financial Performance - Galderma's record financial performance in 2025 includes growth across all product categories and major regional markets, driven by a clear strategic positioning and a science-based innovation approach [4]. - The company projects a net sales growth of 17%-20% for 2026 at constant exchange rates, with core EBITDA margin expected to reach approximately 26% [4]. Market Position - Galderma ranks 11th among global beauty groups with a revenue of $5.207 billion, closing the gap with the 10th place Coty, which is only about $500 million ahead [7]. - The company's growth is attributed to the success of its three main business segments, which complement each other in revenue contribution, profit margins, innovation potential, and resilience [7]. Business Segments - The Injectable Aesthetics segment is the largest revenue source, with net sales of $2.572 billion, showing a year-on-year growth of 11.5% [8]. - The Dermatological Skincare segment generated net sales of $1.449 billion, with a year-on-year increase of 9.3%, driven by strong performances from brands like Cetaphil and Alastin [8]. - The Therapeutic Dermatology segment experienced the fastest growth, with net sales of $1.185 billion, a remarkable year-on-year increase of 50.2%, largely due to the performance of the Nemluvio brand [8]. Strategic Execution in China - China has become a key testing ground for Galderma's strategic execution, with a focus on integrating global products, cross-segment collaboration, and local research to build a comprehensive health management system [9]. - The brand Cetaphil has been a significant driver of growth in China, particularly during promotional events like Double Eleven, outperforming the overall skincare market [9]. Product Innovations - In 2025, Galderma introduced several key products to the Chinese market, including the globally recognized regenerative aesthetic product Sculptra, marking a strategic move into the Chinese regenerative aesthetic market [11]. - The launch of the innovative perioperative skincare brand Alastin further extends the company's offerings from treatment to pre- and post-procedure care, creating a complete "injection + care" loop [11]. Research and Development - Galderma is advancing its R&D investments in China, with a clinical study focusing on the biological impacts of lifestyle and environmental factors on sensitive skin populations [13]. - The company has established a robust R&D network with over 650 personnel across 33 global research bases, emphasizing clinical validation and efficacy in product development [20]. Competitive Landscape - The global beauty industry is witnessing a shift towards medical aesthetics, with major players like L'Oréal and Estée Lauder increasing their focus on this high-growth segment [14][15]. - Galderma's unique vertical integration model allows it to meet diverse consumer needs across different skin conditions and life stages, creating a competitive moat that traditional beauty brands find hard to replicate [21].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market [7]. Core Insights - The company reported a revenue of 1.595 billion yuan for 2025, reflecting a year-on-year growth of 10.6%. However, the net profit attributable to shareholders decreased by 11.1% to 651 million yuan [4][6]. - The fourth quarter of 2025 saw a significant decline in performance, with revenue dropping by 34.1% year-on-year to 300 million yuan and net profit falling by 61.0% to 83 million yuan [4]. - The decline in performance is attributed to several factors, including reduced demand in the medical aesthetics sector, a shift towards functional skincare products leading to lower gross margins, and increased marketing and R&D expenses [4][7]. Financial Data and Profit Forecast - The company’s total revenue is projected to grow from 1.595 billion yuan in 2025 to 2.608 billion yuan by 2027, with corresponding net profits expected to rise from 651 million yuan to 1.137 billion yuan during the same period [6][10]. - The earnings per share (EPS) is forecasted to increase from 5.66 yuan in 2025 to 9.88 yuan in 2027, indicating a positive trend in profitability [6]. - The report highlights a decrease in gross margin from 90% in 2025 to 87.4% by 2027, reflecting competitive pressures in the market [6]. Market Position and Strategic Initiatives - The company is focusing on product innovation, with new product launches aimed at addressing specific consumer needs, such as collagen loss and skin rejuvenation [7]. - Strategic partnerships, such as the collaboration with Yangshengtang Co., are expected to enhance the company's growth potential in various sectors, including medical devices and consumer goods [7]. - The report emphasizes the company's strong technical platform and product portfolio, which are anticipated to provide a competitive edge in the evolving market landscape [7].

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Insights - The company reported a revenue of 1.595 billion yuan for 2025, reflecting a year-on-year growth of 10.6%, while the net profit attributable to shareholders decreased by 11.1% to 651 million yuan [5] - The fourth quarter of 2025 saw a significant decline in performance, with revenue dropping by 34.1% year-on-year to 300 million yuan and net profit down by 61.0% to 83 million yuan, primarily due to reduced demand in the medical aesthetics sector and increased marketing expenses [5][8] - The company is focusing on product innovation and channel expansion, with new collagen products launched in 2025 expected to drive growth despite increased competition in 2026 [8] Financial Data and Profit Forecast - The company’s total revenue is projected to grow from 1.595 billion yuan in 2025 to 2.608 billion yuan by 2027, with corresponding net profits expected to rise from 651 million yuan to 1.137 billion yuan [7] - The gross margin is forecasted to decline slightly from 90.0% in 2025 to 87.4% in 2027, while the return on equity (ROE) is expected to remain strong, around 33% [7] - The price-to-earnings (PE) ratio is projected to decrease from 33 in 2025 to 19 in 2027, indicating potential value appreciation [9]

Financial Data and Key Metrics Changes - Global net revenue for Q4 2025 was $90.3 million, representing a 14% increase compared to Q4 2024, with Jeuveau revenue at $83.1 million and Evolysse at $7.2 million [14] - For the full year 2025, global net revenue reached $297.2 million, up 12% from 2024, marking the sixth consecutive year of double-digit growth [15] - Reported gross margin for Q4 was approximately 66%, with adjusted gross margin at about 67% [16] - GAAP operating expenses for Q4 were $55.1 million, down from $57.3 million in Q3, while non-GAAP operating expenses were $53 million, compared to $49.7 million in Q3 [17][18] - Cash at the end of Q4 was $53.8 million, up from $43.5 million at the end of Q3, driven by strong sales growth and disciplined expense management [19] Business Line Data and Key Metrics Changes - Jeuveau continues to capture over 14% of the U.S. market share, with sustained growth despite a declining procedural environment [9] - Evolysse, launched in 2025, has seen over 3,000 customers purchase the product, expanding the company's presence and share of injectable spend [10] - The company successfully piloted a new portfolio growth rebate program aimed at rewarding practices for increasing their business with Evolus [7] Market Data and Key Metrics Changes - International revenue nearly doubled year-over-year, now representing approximately 8% of total revenue, with strong growth in markets like the U.K. approaching double-digit market share [15][10] - The U.S. injectable procedural volumes declined for only the third time in 25 years, yet Evolus achieved a 12% revenue growth in 2025 [11] Company Strategy and Development Direction - Evolus aims to build a global performance beauty company focused on differentiated brands for cash-paying consumers, with plans to introduce Estyme in Europe and expect FDA approval for Evolysse Sculpt in Q4 2026 [12][26] - The company emphasizes education and training for clinicians, having provided hands-on training to over 14,000 clinicians in 2025 [8] Management's Comments on Operating Environment and Future Outlook - Management noted that the aesthetic market is showing signs of recovery, with expectations for low single-digit growth in the toxin market and gradual recovery in the filler market [55][89] - The company is optimistic about achieving profitability in 2026, with a target revenue between $450 million and $500 million by 2028 [12][25] Other Important Information - Evolus has entered into a revolving credit facility providing up to $30 million for working capital needs, supporting inventory build and preparation for product launches [21][22] - The company plans to transition its primary profitability metric to adjusted EBITDA starting in 2026 to improve comparability with industry peers [24] Q&A Session Summary Question: Has the growth of Evolus been primarily from early adopters or is it starting to broaden? - Management indicated that Evolus is diversifying its customer base, with over 3,000 purchasing accounts and positive feedback on the portfolio rebate program [31] Question: Can Evolus turn around market growth impacted by macro trends? - Management believes that while macro factors affect the market, there are signs of improvement in the filler market, with clinicians adapting to new trends [35] Question: Can you provide details on the rebate program structure? - The rebate program is designed to reward clinics based on purchasing volume, with positive feedback received during the pilot phase [44] Question: How is the toxin market trending based on internal data? - Management noted that the neurotoxin market declined mid to upper single digits in 2025, but there are signs of recovery, especially in the latter half of the year [55] Question: What are the assumptions regarding competitive launches in guidance? - Management acknowledged upcoming competitive launches but emphasized the importance of maintaining focus on their differentiated clinical data and customer satisfaction [62]